EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/76185
58 EW MEETING REPORTER July 2012 Highlights continued from page 57 Reporting live from the 2012 APACRS annual meeting, Shanghai, China mm is good enough." For best results, you also need to achieve a target refraction on the myopic side of about –0.75 D. The fellow eye has a normal flap and standard LASIK procedure. KAMRA is not monovi- sion, it's an enhancement, said Dr. Knorz. Distance and near vision comes in about 1 D better than monovision. Side effects can include glare and halos at night, although this is much less with the current inlay than with prior generations. It's important to explain to patients that the KAMRA inlay provides en- hancement over monovision. Every- thing will be readable, and patients won't need glasses for everyday life, but they may need glasses to read a book for an extended period of time. The best part is the procedure is reversible. "I perform a contact lens trial on everyone," Dr. Knorz said. "Only patients that accept at +1 D over distance correction on the non-dominant eye are candidates for KAMRA." Tan EndoGlide donor insertion device for DSAEK clinical results updated Editors' note: This Meeting Reporter contains original reporting by the EyeWorld news team from the 2012 APACRS annual meeting, Shanghai. Meeting Reporter sponsored by Alcon. The cornea symposium kicked off with Donald Tan, M.D., Singapore, giving a clinical update on DSAEK results with the Tan EndoGlide (Angiotech Pharmaceuticals, Vancouver, Canada) donor insertion device. The EndoGlide is now called the EndoGlide Classic because there are two versions available. It was first launched in 2009 and uses a pull-through glide principle. The CE mark was obtained in Europe in June. "Essentially, it's shaped like a thumb drive," he said. Insertion takes place through a 4.5 mm scleral wound or a 4.9 mm cornea wound. Dr. Tan published the early clinical results in February 2011, but has since updated them. There are currently 100 patients at various stages of follow-up, he said, with 62 eyes at 12 months post-op present- ing with only 14.4% endothelial cell (EC) loss. Dr. Tan and colleagues also evaluated the results and complica- tions of a consecutive series of 45 complicated cases of DSAEK using the EndoGlide to see how useful the device would be. "Some patients had Left to right: Mohan Rajan, M.D., receiving his Film Festival award from Guo Haike, M.D., and Hungwon Tchah, M.D. 2012 APACRS Film Festival winners and judges